NO2679622T3 - - Google Patents

Info

Publication number
NO2679622T3
NO2679622T3 NO13173884A NO13173884A NO2679622T3 NO 2679622 T3 NO2679622 T3 NO 2679622T3 NO 13173884 A NO13173884 A NO 13173884A NO 13173884 A NO13173884 A NO 13173884A NO 2679622 T3 NO2679622 T3 NO 2679622T3
Authority
NO
Norway
Application number
NO13173884A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2679622T3 publication Critical patent/NO2679622T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO13173884A 2011-09-02 2013-06-26 NO2679622T3 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161530516P 2011-09-02 2011-09-02

Publications (1)

Publication Number Publication Date
NO2679622T3 true NO2679622T3 (enExample) 2018-01-20

Family

ID=47116123

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13173884A NO2679622T3 (enExample) 2011-09-02 2013-06-26

Country Status (17)

Country Link
US (1) US9018261B2 (enExample)
EP (2) EP3287438A1 (enExample)
JP (3) JP2014529621A (enExample)
KR (1) KR102024955B1 (enExample)
CN (1) CN103842330B (enExample)
BR (1) BR112014004963A2 (enExample)
CA (1) CA2846510C (enExample)
EA (1) EA201490552A1 (enExample)
ES (1) ES2655942T3 (enExample)
HU (1) HUE035751T2 (enExample)
IN (1) IN2014DN02346A (enExample)
MX (1) MX359259B (enExample)
NO (1) NO2679622T3 (enExample)
PL (1) PL2760821T3 (enExample)
PT (1) PT2760821T (enExample)
SI (1) SI2760821T1 (enExample)
WO (1) WO2013030803A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Cxcr2抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
EP3737366B1 (en) 2018-01-08 2026-02-25 ChemoCentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
MX2022013344A (es) * 2020-04-24 2022-11-30 Dr Falk Pharma Gmbh Formulacion sistemica de un derivado de la piridinona para las enfermedades relacionadas con la tg2.
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506252A (en) 1993-11-17 1996-04-09 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
EP0796243B1 (en) 1994-11-16 1999-01-27 American Home Products Corporation Diaminocyclobutene-3,4-diones
WO1998033763A1 (en) 1997-01-30 1998-08-06 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US5840764A (en) 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US6166050A (en) 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
FR2815345B1 (fr) 2000-10-12 2002-12-13 Servier Lab Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0028844D0 (en) 2000-11-27 2001-01-10 Celltech Chiroscience Ltd Chemical compounds
DE60216229T2 (de) 2001-01-16 2007-10-04 Smithkline Beecham Corp. Il-8-rezeptorantagonisten
JP2004520412A (ja) 2001-01-16 2004-07-08 スミスクライン・ビーチャム・コーポレイション Il−8受容体アンタゴニスト
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
WO2002062761A1 (en) 2001-02-07 2002-08-15 Abbott Laboratories Aminal diones as potassium channel openers
EP1383488A2 (en) 2001-03-30 2004-01-28 SmithKline Beecham Corporation Methods of synthesizing phenol-containing compounds
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
CN1289471C (zh) 2001-04-16 2006-12-13 先灵公司 作为cxc-趋化因子受体配体的3,4-二取代的环丁烯-1,2-二酮
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
WO2003000245A1 (en) 2001-06-22 2003-01-03 Poseidon Pharmaceuticals A/S Compounds for use in disorders associated with mast cell or basophil activity
WO2003080053A1 (en) 2002-03-18 2003-10-02 Schering Corporation Combination treatments for chemokine-mediated diseases
WO2005004915A2 (en) * 2003-07-09 2005-01-20 Boehringer Ingelheim International Gmbh Compositions comprising meloxicam
RU2388756C2 (ru) 2004-01-30 2010-05-10 Шеринг Корпорейшн Кристаллические полиморфные формы лиганда схс-хемокинового рецептора
WO2005076987A2 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
GB0407908D0 (en) * 2004-04-07 2004-05-12 Univ York Ionic liquids
DE102004046492A1 (de) 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE602004021404D1 (de) 2004-12-23 2009-07-16 Gpc Biotech Ag Quadratsäurederivate mit antiproliferativer Wirkung
DE102005001053A1 (de) 2005-01-07 2006-07-20 Merck Patent Gmbh Quadratsäurederivate
US20100130642A1 (en) 2005-02-10 2010-05-27 Wacker Chemie Ag Lacquers containing particles with protected isocyanate groups
EP1853583B1 (en) 2005-02-16 2011-09-07 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
DE102005035741A1 (de) 2005-07-29 2007-02-08 Merck Patent Gmbh Quadratsäurederivate
DE102005035742A1 (de) 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
WO2008005570A1 (en) 2006-07-07 2008-01-10 Schering Corporation 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
JP2010520293A (ja) 2007-03-07 2010-06-10 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド 複素環式部分を含有するメタロプロテアーゼ阻害剤
EP2155670B1 (en) 2007-06-06 2012-04-18 Novartis AG Anti -inflammatory substituted cyclobutenedione compounds
CN101932553A (zh) 2007-07-03 2010-12-29 先灵公司 合成1,2-取代的3,4-二氧代-1-环丁烯化合物的方法和中间体
JP2010532357A (ja) 2007-07-05 2010-10-07 シェーリング コーポレイション 1,2−置換3,4−ジオキソ−1−シクロブテン化合物における制御された結晶サイズのための方法
WO2009012375A2 (en) 2007-07-19 2009-01-22 Wyeth Squarate kinase inhibitors
EP2252327A2 (en) 2007-12-04 2010-11-24 Schering Corporation Methods of treating copd
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
US20110305768A1 (en) * 2008-07-01 2011-12-15 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作c型肝炎病毒抑制劑之巨環吲哚衍生物
HRP20160044T1 (hr) 2008-08-04 2016-02-26 Merck Patent Gmbh Novi spojevi fenilamino izonikotinamida
UA103198C2 (en) * 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
AU2009313867A1 (en) * 2008-11-14 2011-06-30 Patheon Inc. Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low pH and methods of use thereof
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010091543A1 (en) 2009-02-10 2010-08-19 Merck Sharp & Dohme Corp. Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists

Also Published As

Publication number Publication date
SI2760821T1 (en) 2018-02-28
PL2760821T3 (pl) 2018-04-30
KR102024955B1 (ko) 2019-09-24
CN103842330A (zh) 2014-06-04
KR20140059264A (ko) 2014-05-15
JP2014529621A (ja) 2014-11-13
BR112014004963A2 (pt) 2017-03-21
PT2760821T (pt) 2018-01-11
CA2846510C (en) 2019-10-22
ES2655942T3 (es) 2018-02-22
EP3287438A1 (en) 2018-02-28
US9018261B2 (en) 2015-04-28
EP2760821A1 (en) 2014-08-06
WO2013030803A1 (en) 2013-03-07
IN2014DN02346A (enExample) 2015-05-15
EA201490552A1 (ru) 2014-11-28
MX2014002492A (es) 2014-05-28
CA2846510A1 (en) 2013-03-07
JP2019001787A (ja) 2019-01-10
HUE035751T2 (hu) 2018-08-28
JP2017025081A (ja) 2017-02-02
US20140206768A1 (en) 2014-07-24
EP2760821B1 (en) 2017-10-11
JP6612200B2 (ja) 2019-11-27
CN103842330B (zh) 2016-10-19
MX359259B (es) 2018-09-20

Similar Documents

Publication Publication Date Title
BR122020013720A2 (enExample)
BR112013022641A2 (enExample)
BR112013031251A2 (enExample)
BR112013027245A2 (enExample)
BR112013024383A2 (enExample)
BR112013023185A2 (enExample)
BR112013022995A2 (enExample)
BR112013027830A2 (enExample)
BR112013026744A2 (enExample)
BR112013023927A2 (enExample)
BR112013027452A2 (enExample)
BR112013024365A2 (enExample)
BR112013028733A2 (enExample)
AP2016009466A0 (enExample)
BR112013031556A2 (enExample)
BR112013024588A2 (enExample)
BR112013032366A2 (enExample)
BR112013032377A2 (enExample)
BR112013032380A2 (enExample)
BR112013027836A2 (enExample)
BR112013018949A2 (enExample)
BR112013027761A2 (enExample)
BR112013021637A2 (enExample)
NO2679622T3 (enExample)
BR112013025487A2 (enExample)